Prof. Yingfen Ying | Tumors | Women Researcher Award

Prof. Yingfen Ying | Tumors | Women Researcher Award

Wenzhou Medical University | China

AUTHOR PROFILE

Scopus

PROFESSOR YINGFEN YING: A DISTINGUISHED MEDICAL PROFESSIONAL 👩‍⚕️🌍

EARLY ACADEMIC PURSUITS 🎓✨

Professor Yingfen Ying embarked on her academic journey with a strong focus on medical sciences, demonstrating an early aptitude for research and clinical excellence. Her academic foundation was fortified through rigorous education at Wenzhou Medical University, where she gained critical knowledge and skills that paved the way for her distinguished career. She further enriched her expertise as a visiting scholar at the University of British Columbia in Canada, a testament to her global academic vision.

PROFESSIONAL ENDEAVORS 💼🏥

Professor Ying has made significant strides as an Associate Chief Physician and master’s supervisor at Wenzhou Medical University. Her roles extend to various esteemed positions, including:

  • Member of the Obstetrics and Gynecology Rehabilitation Committee, Chinese Rehabilitation Medicine Association.
  • Vice Chairwoman of the Youth Committee, Reproductive Medicine Branch, Zhejiang Society of Traditional Chinese and Western Medicine.
  • Member of the Obstetrics and Gynecology Branch, Zhejiang Society of Translational Medicine.
    She is also affiliated with prominent international organizations, such as the American Society of Reproductive Medicine and the European Society of Human Reproduction and Embryology.

CONTRIBUTIONS AND RESEARCH FOCUS 🔬📚

Professor Ying’s primary research interests center on the mechanistic study of environmental endocrine disruptors and reproductive endocrine diseases. Her investigations delve into the interplay between environmental factors and hormonal imbalances, significantly advancing our understanding of infertility diseases. She has led multiple national and international research projects, including those funded by the National Natural Science Foundation of China.

IMPACT AND INFLUENCE 🌟🌏

Professor Ying’s work has had far-reaching impacts in the field of reproductive medicine. She has authored nearly 30 SCI-indexed papers, contributing valuable insights and advancements to the global medical community. Her research continues to influence clinical practices and guide innovative therapeutic approaches for infertility.

ACADEMIC CITES AND PATENT ACHIEVEMENTS 📜🔑

Professor Ying’s extensive research portfolio has garnered numerous citations in high-impact journals. Additionally, she holds a European patent, exemplifying her contributions to advancing medical technology and treatment methodologies on a global scale.

LEGACY AND FUTURE CONTRIBUTIONS 🌟🚀

As a trailblazer in reproductive medicine, Professor Yingfen Ying’s legacy is defined by her commitment to advancing medical science, mentoring future generations, and improving patient outcomes. Her ongoing projects and international collaborations promise continued breakthroughs, ensuring her work remains at the forefront of reproductive health and endocrine research.

ADDITIONAL HIGHLIGHTS 🌐📖

  • Active member of youth committees in Zhejiang’s medical and scientific communities, fostering innovation and development among emerging scholars.
  • Her dedication to integrating traditional Chinese and Western medicine highlights a holistic approach to patient care and research.
  • International affiliations reflect her commitment to global medical advancements, strengthening ties between diverse medical communities.

CONCLUSION 🌟🏆

Professor Yingfen Ying exemplifies excellence in the fields of reproductive medicine and endocrine research. Her dedication to uncovering the mechanisms of infertility diseases and environmental endocrine disruptors has advanced both science and clinical practice. Through her leadership roles, impactful publications, and international collaborations, she has established herself as a global authority and advocate for holistic and innovative approaches to healthcare.

 

📊🔬NOTABLE PUBLICATION:
  • Title: Halogen atoms determine the inhibitory potency of halogenated bisphenol A derivatives on human and rat placental 11β-hydroxysteroid dehydrogenase 2
    Authors: Shi, L., Zhang, B., Ying, Y., Ge, R.-S., Liu, Y.
    Journal: Food and Chemical Toxicology
    Year: 2023

 

  • Title: Inhibitory effects of parabens on human and rat 17β-hydroxysteroid dehydrogenase 1: Mechanisms of action and impact on hormone synthesis
    Authors: Chen, Z., Gong, C., Tang, Y., Ge, R.-S., Ying, Y.
    Journal: Toxicology
    Year: 2024

 

  • Title: Per- and polyfluoroalkyl substances inhibit human and rat 17β-hydroxysteroid dehydrogenase 1: Quantitative structure-activity relationship and molecular docking analysis
    Authors: Wen, C., Chen, H., Tang, Y., Chen, C., Chen, S.
    Journal: Ecotoxicology and Environmental Safety
    Year: 2024

 

  • Title: Leydig cell development in pubertal male rats is blocked by perfluorotetradecanoic acid through decreasing AMPK-mTOR-autophagy pathway
    Authors: Tang, Y., Shi, L., Wang, S., Ge, R.-S., Ying, Y.
    Journal: Toxicology Letters
    Year: 2023

 

  • Title: Structure-activity relationship and in silico docking analysis of dicarboximide fungicides on 17β-hydroxysteroid dehydrogenase 1 of human, rat, and pig
    Authors: Chen, H., Chen, S., Tang, Y., Ge, R.-S., Duan, P.
    Journal: Ecotoxicology and Environmental Safety
    Year: 2025

Dr. Hang Hu – Cancer Photodynamic Therapy – Best Researcher Award

Dr. Hang Hu - Cancer Photodynamic Therapy - Best Researcher Award

Changzhou University - China

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Hang Hu initiated his academic journey with a Bachelor's degree in Applied Chemistry from Hubei University. Subsequently, he pursued higher education, obtaining both a Master's degree and a Doctor's degree in Organic Chemistry and Biopharmaceutical Engineering at Huazhong University of Science and Technology. These early academic pursuits laid the foundation for his specialization in cancer photodynamic therapy.

PROFESSIONAL ENDEAVORS

Hang Hu ventured into professional academia, securing a teaching position at the School of Pharmacy, Changzhou University. His professional endeavors aligned with his research interests, focusing specifically on advancing cancer photodynamic therapy and leveraging his expertise to contribute to the development of anticancer drug delivery systems.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER PHOTODYNAMIC THERAPY

Hang Hu's significant contributions revolve around his involvement in a groundbreaking project during his graduate studies. This project aimed to construct anticancer drug delivery systems using hydroylethyl starch-based materials, leading to the development of nanomedicines tailored for cancer photodynamic therapy. His subsequent research at Changzhou University focused on novel strategies to potentiate photodynamic therapy (PDT), addressing challenges such as tumor hypoxia, high intracellular glutathione (GSH), and insufficient photosensitizer uptake.

IMPACT AND INFLUENCE

Hang Hu's impact is underscored by the recognition his research has garnered in esteemed journals such as Materials Today Bio, Journal of Colloid and Interface Science, Nanoscale, ACS Applied Materials & Interfaces, Chemical Engineering Journal, and Advanced Healthcare Materials. His work addresses critical limitations in cancer treatment methodologies, particularly in the realm of photodynamic therapy.

ACADEMIC CITES

Hang Hu's academic achievements are evident through his co-authorship of over 40 SCI papers and the application of over 30 invention patents. His prolific publication record, mainly in the fields of anticancer drug delivery and cancer photodynamic therapy, serves as a valuable reference within the scientific community.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

Hang Hu's legacy is characterized by a commitment to excellence and innovation in cancer therapy, particularly in the field of photodynamic therapy. His work has provided new insights into the design of effective cancer photodynamic therapy nanomedicines. Looking ahead, Hang Hu is poised to continue making significant contributions to enhance cancer treatment methodologies, leaving a lasting impact on the development of novel and effective therapeutic strategies. His dedication to addressing critical challenges in cancer therapy sets the stage for a continued legacy of innovative research.

NOTABLE PUBLICATIONS

Polyethylene glycol modified protamine-chlorin e6 conjugate nanoparticles for enhanced cancer photodynamic therapy. 2024

Synthesis of curcumin derivatives for suppression of castration-resistant prostate cancer. 2024

Targeted Delivery of Doxorubicin to Hepatoma Cells by Lactobionic Acid-Decorated Dual Redox-Responsive Polyethylene Glycol-Doxorubicin Nanoparticles. 2023

Synthesis and evaluation of curcumin functionalized calcium polyphosphate for bone regeneration. 2023

Reduction-responsive worm-like nanoparticles for synergistic cancer chemo-photodynamic therapy. 2023